From Chinese medicine to anticancer drugs

被引：22

作者：

Bradbury, J

机构：

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 17期

关键词：

D O I：

10.1016/S1359-6446(05)03587-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：1131 / 1132

页数：2

相关论文

共 5 条

[1] Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases [J].

Hoessel, R ;

Leclerc, S ;

Endicott, JA ;

Nobel, MEM ;

Lawrie, A ;

Tunnah, P ;

Leost, M ;

Damiens, E ;

Marie, D ;

Marko, D ;

Niederberger, E ;

Tang, WC ;

Eisenbrand, G ;

Meijer, L .

NATURE CELL BIOLOGY, 1999, 1 (01) :60-67

[2] From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors [J].

Jautelat, R ;

Brumby, T ;

Schäfer, M ;

Briem, H ;

Eisenbrand, G ;

Schwahn, S ;

Krüger, M ;

Lücking, U ;

Prien, O ;

Siemeister, G .

CHEMBIOCHEM, 2005, 6 (03) :531-540

[3] Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells [J].

Nam, S ;

Buettner, R ;

Turkson, J ;

Kim, D ;

Cheng, JQ ;

Muehlbeyer, S ;

Hippe, F ;

Vatter, S ;

Merz, KH ;

Eisenbrand, G ;

Jove, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (17) :5998-6003

[4] Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China [J].

Xiao, ZJ ;

Hao, YS ;

Liu, BC ;

Qian, LS .

LEUKEMIA & LYMPHOMA, 2002, 43 (09) :1763-1768

[5] The stats of cancer - New molecular targets come of age [J].

Yu, H ;

Jove, R .

NATURE REVIEWS CANCER, 2004, 4 (02) :97-105